Chinese researchers recently presented evidence that the consumption of foods and ingredients rich in selenium can improve the health of people with Alzheimer’s disease, Xinhua reported, citing Agerpres.

A new study conducted by the Institute of Microbiology of the Guangdong Academy of Sciences and published in the journal Critical Reviews in Food Science and Nutrition claims that foods high in selenium can suppress inflammation and oxidative stress, thus demonstrating the potential of the new strategy. nutrition for patients with Alzheimer’s disease.

Alzheimer’s disease is a neurological disease characterized by memory loss and reduced learning ability, which can affect a person’s ability to perform daily activities and can impair quality of life. Selenium-rich foods are gaining interest in Alzheimer’s research.

A team of researchers from the Institute of Microbiology of the Guangdong Academy of Sciences and other institutions have proposed a potential intervention mechanism with selenium-rich foods to improve the health status of people affected by this disease.

Selenium-rich ingredients are ubiquitous in many plants and microorganisms such as crucifers, yeasts, and fungi.

A new drug for the treatment of Alzheimer’s disease is approved in the United States

The study, published by Chinese scientists, comes after the United States health authorities approved a new Alzheimer’s drug designed to reduce cognitive decline in patients suffering from the neurodegenerative disease in January.

The new treatment, lecanemab, which will be marketed as Leqembi, is now recommended by the US Food and Drug Administration (FDA) for patients whose disease has not yet reached a very advanced stage.

The drug is intended for patients with mild cognitive impairment or early Alzheimer’s dementia, a population that doctors believe is a small fraction of the roughly 6 million Americans currently living with the disease, which includes memory loss.

This study showed that Leqembi, given by infusion, slowed the rate of cognitive decline in patients with early Alzheimer’s disease by 27% compared to a placebo. But the study also found serious side effects: some patients had brain hemorrhages.

In addition, at least one person treated died, and nearly 13 percent of patients treated with Leqembi in the study experienced brain swelling.